Genprex to Present at Upcoming September Investor Conference

Rhea-AI Summary

Genprex, Inc. will present an overview of its gene therapies for cancer and diabetes at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be given by Ryan Confer, the company's Chief Financial Officer, on September 13, 2023, at 3:00 p.m. ET. The presentation will be available for replay on Genprex's website. Investors can also schedule one-on-one meetings with Genprex management through the conference portals or by contacting Investor Relations.

Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes

AUSTIN, Texas, Sept. 7, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Financial Officer, Ryan Confer, will  be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming H.C. Wainwright 25^th Annual Global Investment Conference.

Event: H.C. Wainwright 25th Annual Global Investment Conference
Conference Dates: Sep. 11 – 13, 2023
Presentation Date: Wednesday, Sep. 13, 2023
Presentation Time: 3:00 p.m. ET
Presenter: Ryan Confer, Genprex's Chief Financial Officer
Presentation link: https://bit.ly/3sFJE6U

A recording of this presentation will be available for replay on Genprex's website for a period of time.

Mr. Confer will deliver an overview of the Company's pioneering gene therapies for cancer and diabetes and will be available for in-person one-on-one meetings with investors through the conference platform.  

For those interested in meeting Genprex management during the conference, please request a meeting through the conference portals or reach out to Investor Relations at investors@genprex.com.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral ONCOPREX® Nanoparticle Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.The Company's lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the Food and Drug Administration ("FDA"), and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements 
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2022.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-at-upcoming-september-investor-conference-301920282.html

SOURCE Genprex, Inc.

FAQ

What is the name of the company presenting at the conference?

The company presenting at the conference is Genprex, Inc.

What is the focus of Genprex's gene therapies?

Genprex's gene therapies are focused on cancer and diabetes.

Who will be giving the presentation?

The presentation will be given by Ryan Confer, Genprex's Chief Financial Officer.

When will the presentation take place?

The presentation will take place on September 13, 2023.

Where can investors watch the presentation?

Investors can watch the presentation on Genprex's website.

Can the presentation be replayed?

Yes, a recording of the presentation will be available for replay on Genprex's website.

How can investors schedule one-on-one meetings with Genprex management?

Investors can schedule one-on-one meetings with Genprex management through the conference portals or by contacting Investor Relations.